ABOUT US AND OUR MISSION

BioClonetics Immunotherapeutics is a biotechnology company with a proprietary methodology and expertise for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. From this methodology, we have created proprietary cell lines that produce fully human monoclonal antibodies that target and neutralize infectious diseases including HIV, influenza, tetanus and diphtheria.
 
The company founder, Dr. Joseph Cotropia, MD, pioneered the company proprietary method for creating human cell lines that produce human antibodies directed against many infectious diseases. One cell (designated as CLONE 3) has been demonstrated in multiple tests to neutralize the HIV virus. The Company is in the final development of this monoclonal antibody that is non-toxic and 100% effective against over 92% of all strains and viral subtypes of HIV-1 against which it has been tested.
 
This human antibody can be used as an immuotherapeutic treatment for individuals with HIV/AIDS. The antibody may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current ARV therapy for several significant reasons: (1) the therapy will be effective and non-toxic, (2) it will not require lifetime treatment and (3) it will be far less expensive.
 
Thus, for the patient, the Clone 3 antibody immunotherapy will be remarkably different -- it will be safer, provide a much needed immunotherapeutic cure rather than requiring lifelong treatment, and costs substantially less than current ARV therapy.
 
The Company also has created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus and diphtheria. As a part of our mission, the Company is testing these antibodies to prepare them for use as therapies and vaccines against these diseases. 


COMMITTED TO BETTER THERAPIES

FOR PATIENTS THROUGH THE USE OF

MONOCLONAL ANTIBODIES